- Home
- FORA vs CGTX Comparison
FORA vs CGTX Comparison
Compare FORA & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FORA | CGTX |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.4M | 132.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | FORA | CGTX |
|---|---|---|
| Price | $2.10 | $1.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $3.33 |
| AVG Volume (30 Days) | 30.1K | ★ 896.2K |
| Earning Date | 11-14-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $28,106,911.00 | N/A |
| Revenue This Year | $47.82 | N/A |
| Revenue Next Year | $10.11 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 37.47 | N/A |
| 52 Week Low | $1.64 | $0.22 |
| 52 Week High | $4.03 | $3.83 |
Technical Indicators
Market Signals| Indicator | FORA | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.17 | 46.72 |
| Support Level | $2.06 | $1.33 |
| Resistance Level | $2.12 | $1.62 |
| Average True Range (ATR) | 0.05 | 0.11 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 53.33 | 32.56 |
Price Performance
Historical ComparisonAbout FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.